New to The Street / Newsmax TV Announces Its 274th Broadcast, 8 Interviews, Airing Sunday, December 12, 2021, 10–11 A.M. ET

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) — FMW Media’s New to The Street /  Newsmax TV announces the broadcasting line-up of its national syndicated TV show this Sunday, December 12, 2021, airing 10–11 A.M. ET.

New to The Street’s 274th TV show line-up, features eight (8) interviews of the following Companies and their businesses representatives:

1). Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) interview, Mr. Seth Lederman, CEO.

2). Rego Payments Architectures, Inc.’s (OTCQB: RPMT) interview, Mr. Dan Aptor, Head of Strategy.

3). Gaming –’s (CRYPTO: SPS) ($SPS) interview, Mr. Jesse Reich (“Aggroed”), CEO.

4). Cryptocurrency – Cosmos Signal’s (CRYPTO: ATOM) ($ATOM) “All-New Quarterly Keynote” video presentation,  Mr. Peng Zhong, CEO of Tendermint, Mr. Sane Lebrun, Vice-president Growth of Tendermint, and Ms. Linda Chen, Vice-president Operations, Forte.

5). GlobeX Data Ltd.’s (OTCQB: SWISF) (CSE: SWIS) (FRA: GDT) interview, Mr. Alain Ghiai, CEO.

6). Cryptocurrency – Pink Panda Holdings, Inc.’s (CRYPTO: PINKPANDA) ($PINKPANDA) interviews, Adam Carlton, Founder and CEO, and Karim Luqam, Senior Exchange Architect.

7). Cryptocurrency – Rewards Bunny’s (CRYPTO: RBUNNY) ($RBUNNY) interviews, Jacky Goh, Co-Founder and CEO, and Ivaylo Yovkov, Co-Founder and COO.

8). Sekur’s® (a division of GlobeX Data, Ltd.) “SPECIAL SEGMENT – Weekly Hack” interview, internet privacy expert Mr. Alain Ghiai, CEO.


New to The Street TV airs the NASDAQ in-studio interview with Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) CEO, Seth Lederman. Talking with “New to The Street” TV Anchor Jane King, Mr. Lederman discusses the Company’s COVID-19 vaccine, antiviral pharmaceutical, skin test, and “Long” COVID-19 novel treatments and products. The Company’s TNX-1800, a live virus vaccine in development, gives long-term protection from COVID, and Seth compares the TNX -1800 live vaccine versus mRNA vaccines. The TNX-3500, an oral antiviral pharmaceutical currently in development, shows in tissue cultures as highly potent compared to competitors’ antiviral products in the marketplace. He sees clinical solid test results from combining the TNX-3500 oral product with Remdesivir. Seth gives viewers information about upcoming studies in other focused products currently in development, including a detox product for cocaine. With about $183M in cash, Seth sees Tonix Pharmaceutical in great shape heading into 2022.


Click here to continue reading the full article on Globe Newswire